Search jobs Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights
Continued to advance our portfolio of anti-TIGIT antibodies: On track for the ARC-7 interim analysis for domvanalimab in 2Q21, and the first patient was dosed with AB308 in combination with zimberelimab
Presented promising PFS and OS data for etrumadenant in the ≥3L metastatic colorectal cancer setting at AACR
Initiated the randomized portion of our ARC-8 study evaluating AB680, our first-in-class small molecule CD73 inhibitor, in pancreatic cancer following rapid completion of enrollment of the dose-expansion portion of the study
Presented preclinical data on a novel series of HIF-2α